GW Pharmaceuticals Plc (GWPH)

161.96
1.20 0.71
NASDAQ : Health Technology
Prev Close 163.11
Open 162.50
Day Low/High 158.06 / 162.50
52 Wk Low/High 90.14 / 196.00
Volume 77.80K
Avg Volume 358.10K
Exchange NASDAQ
Shares Outstanding 30.72M
Market Cap 5.08B
EPS -9.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer says the market can have many winners.

Stocks Ready to Benefit From Rising Marijuana Legalization, Usage

Stocks Ready to Benefit From Rising Marijuana Legalization, Usage

Legalization of marijuana for medical reasons or otherwise is already on the ballot in Arkansas, California, North Dakota and several other states.

Pot Is on the Ballot in Election 2016, but Investors Should Proceed With Caution

Pot Is on the Ballot in Election 2016, but Investors Should Proceed With Caution

Marijuana is on the ballot in several states this election cycle, and its approval could be a boon for those in the business -- though obstacles remain.

Here's Why These 3 Cheap Marijuana Stocks May Quadruple in Price

Here's Why These 3 Cheap Marijuana Stocks May Quadruple in Price

Shares of these cannabis companies are ready for huge growth if November is a successful month for legalization.

GW Pharmaceuticals Stock Can Make Even More Gains -- Here's Why

GW Pharmaceuticals Stock Can Make Even More Gains -- Here's Why

The company's share price has increased 1,500% since 2013.

Rev's Forum: Stock Pickers Have Some Opportunities

Rev's Forum: Stock Pickers Have Some Opportunities

But the buyers are still unable to produce sustained momentum.

GW Pharmaceuticals Is Taking Off as the Cannabis Industry Grows

GW Pharmaceuticals Is Taking Off as the Cannabis Industry Grows

Analysts are predicting that the legal pot market could reach $6.7 billion in sales this year.

Jim Cramer -- Gilead Needs to Make an Acquisition

Jim Cramer -- Gilead Needs to Make an Acquisition

Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.

Cramer: How Do You Play This Answer to the Opiate Epidemic?

Cramer: How Do You Play This Answer to the Opiate Epidemic?

GW Pharma could be the answer to an opiate addiction that isn't understood.

Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology

Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology

Cramer continues to back Apple and says Align Technology is a stock to buy now.

Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter

Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter

Investors hate uncertainty, Cramer says, but uncertainty creates bargains.

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish

GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish

GW Pharmaceuticals (GWPH) said on Monday its seizure drug epidiolex had positive results in a late-stage clinical trial.

Stephen King's Maximum Oversold (by Midweek)

And we'll get FOMC and BoJ then.

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

Cramer is sticking with International Paper and likes Advanced Micro Devices.

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

This is not the time to sell in a panic, Cramer says.

4 Companies Likely to Benefit From Widening Legalization of Marijuana

4 Companies Likely to Benefit From Widening Legalization of Marijuana

The marijuana market is heating up as marijuana usage for medical and recreational purposes gains legitimacy.

GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation

GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation

GW Pharmaceuticals (GWPH) reportedly hired Morgan Stanley after it was approached by several companies about a possible takeover.

'Mad Money' Lightning Round: Weight Watchers Is Not for Me

'Mad Money' Lightning Round: Weight Watchers Is Not for Me

Cramer says sell Stryker and buy Zimmer Biomet, and take Randgold over Barrick Gold.

Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer

Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer

The economy needs consumers to buy, buy, buy but so far consumers have been all over the map, Cramer says.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath

Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath

Investors should stick with buying stocks in the utilities and consumer staples sectors, which rose higher in the aftermath of the Brexit vote and avoided the massive volatility.

Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures

Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures

Shares of GW Pharmaceuticals are on the rise after the company announced this morning positive Phase 3 results for its Epidiolex for the treatment of Lennox-Gastaut syndrome, or LGS.